AABB will host a Hot Topic Discussion on Aug. 18 to discuss the potential impact of long-acting, injectable cabotegravir as pre-exposure prophylaxis (PrEP) for the prevention of HIV. The Food and Drug Administration approved the injectable medication (Apretude, Viiv Healthcare) in December 2021.
Based on concerns and questions from hospitals and blood centers about inventory management strategies, AABB has confirmed its understanding with the Food and Drug Administration to help members identify existing flexible shipping options that are widely misunderstood.
The Food and Drug Administration issued a revised final guidance on Friday that provides updated recommendations on the use of COVID-19 convalescent plasma (CCP) related to the December 2021 emergency use authorization (EUA) for CCP.
The Food and Drug Administration revised the emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) on Dec. 28 to permit the use of high-titer CCP for treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment.
AABB recently launched a new toolkit to assist transfusion services that must register with the Food and Drug Administration for the first time because they are implementing a bacterial detection test to extend the expiration of platelets to day 6 or 7 and relabel the platelets.